| Old Articles: <Older 2951-2960 Newer> |
|---|
 |
Pharmaceutical Executive
June 1, 2006
Paul Kidwell |
Public Relations: Targeting Partners PR can facilitate business partnerships between biotechnology and pharmaceutical companies by targeting messages to key players.   |
Pharmaceutical Executive
June 1, 2006
Ron Buzzeo |
Sales Management: Gifting Laws Cause Regulatory Woe New legislation forces drug companies to rethink marketing and sales initiatives. |
Pharmaceutical Executive
June 1, 2006 |
Back Page: The "Help is Here" Express The Partnership for Prescription Assistance is a one-stop-shop for industry-sponsored assistance programs. |
Pharmaceutical Executive
June 1, 2006
Jill Wechsler |
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. |
Pharmaceutical Executive
June 1, 2006
Patrick Clinton |
From the Editor: Forecast -- and Fast The glory of the years to come will be in new science, new medicines, and new cures. But someone has to do the hard, scary work of guaranteeing the survival of the businesses that bring new cures to patients. |
Pharmaceutical Executive
June 1, 2006
Sarah Houlton |
Global Report: People Problems A recent clinical trials disaster is causing UK regulators to consider revising its guidelines for Phase I human studies for biologics. However, in many cases, potential solutions present additional problems. |
Pharmaceutical Executive
June 1, 2006
Paul Chang |
Thought Leader: Chipping Away at Counterfeiting RFID technology promises to help FDA stem the tide of phony medicines. But that's just the beginning. It's also a great supply-chain management tool. |
Pharmaceutical Executive
June 1, 2006
Jim Rittenburg |
Toolkit: Safety in Numbers Mass serialization can protect the drug supply. But the next step forward will come from barcoding, not RFID. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
The Motley Fool
June 6, 2006
S.J. Caplan |
American Medical Greenlights a Merger The med-tech firm is well positioned to build on a strong market presence, and its price did drop yesterday. But near-term pains can best be avoided by not chasing this stock until both the financing terms of the Laserscope deal and the disposition of its aesthetics business are clarified. |
| <Older 2951-2960 Newer> Return to current articles. |
